Efforts to target TG2/FN/integrin complexes have yielded several small molecules with potent activity against cell adhesion to the matrix, initiation of outside-in signaling, and disruption of cancer cell seeding to peritoneal surfaces [52,53]. The gene discussed is TGM2; the disease is cancer.